Lantheus Holdings Inc (NASDAQ:LNTH) has received a consensus recommendation of “Hold” from the six analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.50.
LNTH has been the subject of several recent analyst reports. ValuEngine lowered Lantheus from a “hold” rating to a “sell” rating in a research note on Wednesday, October 31st. BidaskClub upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th.
In related news, insider Cesare Orlandi sold 7,055 shares of Lantheus stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $18.01, for a total value of $127,060.55. Following the completion of the transaction, the insider now owns 86,064 shares in the company, valued at approximately $1,550,012.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.20% of the stock is owned by insiders.
Shares of Lantheus stock opened at $18.21 on Wednesday. The company has a quick ratio of 2.87, a current ratio of 3.50 and a debt-to-equity ratio of 4.76. Lantheus has a twelve month low of $12.59 and a twelve month high of $24.45. The stock has a market capitalization of $721.22 million, a P/E ratio of 18.21, a price-to-earnings-growth ratio of 4.36 and a beta of 1.42.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, October 30th. The medical equipment provider reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.18 by $0.06. Lantheus had a return on equity of 83.95% and a net margin of 36.75%. The firm had revenue of $88.90 million during the quarter, compared to analyst estimates of $83.53 million. During the same quarter in the previous year, the business earned $0.24 EPS. Lantheus’s revenue for the quarter was up 11.1% compared to the same quarter last year. Analysts forecast that Lantheus will post 0.86 earnings per share for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Read More: What are different types of coverage ratios?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.